Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut check: Semaglutide's hidden effect on obesity bacteria

NCT ID NCT07323134

Knowledge-focused Sponsor: Beijing Chao Yang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will give 40 obese adults semaglutide for 12 weeks to see how it changes their gut bacteria. Researchers will use stool samples and lab tests to understand the effects. The goal is to learn how semaglutide works on gut flora, not to test weight loss directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide injection
What this could lead to
If successful, this could reveal how semaglutide changes gut bacteria, possibly pointing to new ways to treat obesity.
What could go wrong
This is a small, early-stage study (40 people) that only looks at gut bacteria changes, not weight loss. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Obese patients who visited the Department of Endocrinology of Beijing Chaoyang Hospital Affiliated to Capital Medical University

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 to 60 years old; * BMI ≥ 30kg/m²; * At least one self-reported history of unsuccessful lifestyle weight loss; * Subjects who agree to participate in the project and sign the informed consent form. Exclusion Criteria: * Weight changes within 3 months prior to screening (self-reported) \>5%; * Having received any drug treatment for obesity within the three months prior to screening; * The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes; * Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and/or other gastrointestinal motility drugs within 3 months prior to screening; * Previously diagnosed overweight or obesity due to endocrine causes, such as Cushing's syndrome, etc; * Triglycerides ≥500mg/dL (5.65mmol/L) during screening; * It is known that there are clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), a history of gastrointestinal diseases and surgical history; * Abnormal thyroid function; * History of mental illness; * History of multiple endocrine tumors or medullary thyroid cancer, family history, or calcitonin ≥6pg/mL; * Abnormal liver function during screening, that is, alanine aminotransferase and/or aspartate aminotransferase \> 3\*ULN; * Abnormal renal function during screening, that is, the estimated glomerular filtration rate is less than 60mL/min/1.75m2; * History of cardiovascular diseases; * History of malignant tumors; * Pregnancy or lactation; * As determined by the researcher, there are other physical, psychological or other conditions that make one unsuitable to participate in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.